TPA or Perfluoropropane for Submacular Hemorrhage in AMD
This randomized clinical trial investigates if tissue plasminogen activator (TPA) or perfluoropropane improve visual acuity or resolution of submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) in eyes treated with ranibizumab.